Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term administration & dosage. Found 206 abstracts

no pagination
Dell DD. Deep vein thrombosis in the patient with cancer. Clinical journal of oncology nursing. 2002 Jan;6(1):43-6.
Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec;8(12):3718-27.
Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicoloau N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol. 2002 Oct;20(19):4015-21.
Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul;20(13):2918-9.
Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol. 2002 Feb 15;20(4):1115-27.
Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer letters. 2002 Oct 08;184(1):7-12.
Ma J, Reed KA, Gallo JM. Cells designed to deliver anticancer drugs by apoptosis. Cancer Res. 2002 Mar;62(5):1382-7.
Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer. 2002 May;2(1):43-50.
Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 2002 Dec 04;94(23):1773-9.
Ozols RF, Markman M, Thigpen JT. ICON3 and chemotherapy for ovarian cancer. Lancet (London, England). 2002 Dec 21;360(9350):2086-7; author reply 2088.
Pollack A, Kuban DA, Zagars GK. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):22-30; discussion 30-1.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15;20(12):2895-903.
Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep;50(3):243-50.
Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR. Sequence-dependent synergistic cytotoxicity of ET-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002 Dec;62(23):6909-15.
Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in medicine. 2001 Jul 30;20(14):2079-90.
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current treatment options in oncology. 2001 Apr;2(2):157-67.
Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15;19(4):1021-9.
Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001 Jan;19(1):89-92.
Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol. 2001 Aug;48(2):169-76.
Guttormsen AB, Ueland PM, Kruger WD, Kim CE, Ose L, Folling I, Refsum H. Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype. Am J Med Genet. 2001 May;100(3):204-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term administration & dosage

administration & dosage Human drug therapy Female Middle Age US Gov't Support-PHS therapeutic use adverse effects Aged Antineoplastic Combined Chemotherapy Protocols Adult Male Drug Administration Schedule pathology Breast Neoplasms Non-US Gov't Support Antineoplastic Agents chemically induced metabolism Cisplatin pharmacology Animal drug effects Drug Dose-Response Relationship therapy pharmacokinetics Paclitaxel Neoplasm Drug Resistance genetics Treatment Outcome administration & adverse Ovarian Neoplasms effects 80 and over Aged Combined Modality Therapy Fluorouracil mortality Risk Assessment Isoquinolines dosage Doxorubicin Drug Delivery Systems Tissue Distribution P-Glycoprotein complications toxicity surgery Oral Administration Apoptosis radiotherapy Intravenous Infusions Thrombocytopenia Mutation diagnosis Survival Analysis Carboplatin analogs & Tamoxifen derivatives Rats Heterozygote analogs & derivatives blood Xenograft Model Antitumor Assays Sprague-Dawley Rats Prostatic Neoplasms Local Neoplasm Recurrence Adolescent Enzyme Inhibitors Follow-Up Studies Neoplasms Cultured Tumor Cells antagonists & inhibitors Hypotension Intestinal Absorption GABA-A Receptors Unsaturated Fatty Acids Interferon Inducers Genotype Amifostine Camptothecin Matched-Pair Analysis Methionine Area Under Curve Polylysine Chelating Agents secretion Clinical Trials Granulocyte Colony-Stimulating Factor Nude Rats Unsaturated Dietary Fats Experimental Mammary Neoplasms Interleukin-2 Protective Agents Hematopoietic Stem Cell Transplantation Liver Neoplasms Pain Axilla deficiency Nude Mice Liver prevention & etiology Endothelial Growth Factors Heparin biosynthesis cytology Cultured Cells Biological Availability Feasibility Studies Mesna Radiotherapy Dosage Isoenzymes methods Brain Neoplasms Inhibitory Concentration 50 Adenocarcinoma Randomized Controlled Trials Radiotherapy Practice Guidelines Sulfonamides Kidney Neoplasms Antineoplastic Antimetabolites Peripheral Nerves Chromium ATP-Binding Cassette Transporters Methotrexate Prognosis Case-Control Studies Neutropenia Homocysteine immunology CD56 Antigens BRCA2 Genes Androgen Antagonists DNA Poly I-C Case Report Fluorescence In Situ Hybridization BRCA1 Genes Adjuvant Chemotherapy Anticarcinogenic Agents urine physiology Multiple Drug Resistance Neoplasm Proteins Risk Factors Antibodies Reference Values
Last updated on Friday, January 03, 2020